Essentials for Clinicians: Gastrointestinal Tract Tumours

Josep Tabernero

Vall d’Hebron University Hospital and Institute of Oncology (VHIO) Barcelona, Spain

Andrés Cervantes

Department of Hematology and Medical Oncology
Biomedical Research Institute INCLIVA, University of Valencia
Valencia, Spain

Henk van Halteren

Department of Medical Oncology, Admiraal de Ruijter Hospital
Goes, The Netherlands

Series editor: Michele Ghielmini

Oncology Institute of Southern Switzerland, Ospedale San Giovanni
Bellinzona, Switzerland

Contributors

Chapter 1 – Biology of cancer development in the GI tract

HG Palmer - Stem Cells and Cancer Laboratory, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Chapter 2 - Diagnosis, staging, response assessment and interventional radiology in GI tumours

A Laghi - Department of Radiological Sciences, Oncology and Pathology, “Sapienza” University of Rome; I.C.O.T. Hospital, Latina, Italy

D Bellini - Department of Radiological Sciences, Oncology and Pathology, “Sapienza” University of Rome; I.C.O.T. Hospital, Latina, Italy

Chapter 3 - Oesophageal cancer     

F Lordick - University Cancer Center Leipzig (UCCL), University Hospital Leipzig, Leipzig, Germany

W Allum - Department of Surgery, Royal Marsden NHS Foundation Trust, London, UK

K Haustermans - Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, and Department of Oncology, KU Leuven, Leuven, Belgium

F Carneiro - Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal

Chapter 4 - Gastric cancer   

V Gambardella - Department of Medical Oncology, Biomedical Research, Institute INCLIVA, University of Valencia, Valencia, Spain

N Tarazona - Department of Medical Oncology, Biomedical Research, Institute INCLIVA, University of Valencia, Valencia, Spain

A Cervantes - Department of Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

Chapter 5 – Colon Cancer

J Raimbourg - ICO R Gauducheau, University Medical School Nantes, Nantes, France

JY Douillard - ICO R Gauducheau, University Medical School Nantes, Nantes, France

Chapter 6 – Rectal Cancer

S Roselló - Department of Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

A Cervantes - Department of Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

Chapter 7 - Pancreatic cancer          

T Seufferlein - Department of Internal Medicine I, Ulm University, Ulm, Germany

F Mornex - Department of Radiation Oncology, Centre Hospitalier Lyon Sud, University Claude Bernard, Lyon, France

T Hackert - Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany

MW Büchler - Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany

Chapter 8 - Hereditary colorectal cancer syndromes

L Moreira - Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, University of Barcelona, Barcelona, Spain

F Balaguer - Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, University of Barcelona, Barcelona, Spain

J Balmaña - Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain

Chapter 9Aetiology and epidemiology

CA González - Unit of Nutrition and Cancer, Department of Cancer Epidemiology, Catalan Institute of Oncology, Barcelona, Spain

A Agudo - Unit of Nutrition and Cancer, Department of Cancer Epidemiology, Catalan Institute of Oncology, Barcelona, Spain

Chapter 10 New targets and new drugs in colorectal cancer

S De Dosso - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

J Tabernero - Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain

Chapter 11 - Primary liver cancer and biliary cancer

M Reig - Barcelona Clínic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

A Liccioni - Barcelona Clínic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

J Bruix - Barcelona Clínic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

Chapter 12 - Uncommon GI tumours: small intestine and anal cancer

C Verslype - Digestive Oncology, University Hospitals Leuven, Leuven, Belgium

H Prenen - Digestive Oncology, University Hospitals Leuven, Leuven, Belgium

Chapter 13 - Neuroendocrine GI tract tumours

K Oberg - Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

Declarations of interest

A Agudo: No conflicts of interest.

W Allum: No conflicts of interest.

F Balaguer: No conflicts of interest.

J Balmaña: No conflicts of interest.

D Bellini: No conflicts of interest.

J Bruix: Consultancy: Gilead, Abbvie, Kowa, Bayer, BTG, Arqule, Terumo, BMS, Boehringer Ingelheim, Kowa, Novartis, OSI, Roche, Onxeo.

MW Büchler: No conflicts of interest.

F Carneiro: No conflicts of interest.

A Cervantes: No conflicts of interest.

S De Dosso: No conflicts of interest.

JY Douillard: Advisory boards, Speaker bureaux, Symposia presentations: Amgen, Bayer, Roche, Sanofi, Sirtex, Takeda, Merck Serono (Research funding to the institution).

V Gambardella: No conflicts of interest.

CA González: No conflicts of interest.

T Hackert: No conflicts of interest.

K Haustermans: No conflicts of interest.

A Laghi: Speaker: Bracco, Guerbet, GE Healthcare, Takeda, Alfa Wassermann; Consultant: Covidien.

A Liccioni: No conflicts of interest.

F Lordick: Research support: Boehringer Ingelheim, GSK, Fresenius Biotech. Advisory honoraria: Amgen, Biontech, BMS, Eli Lilly, Ganymed, Merck Serono, Merck-MSD, Nordic, Roche. Travel support: Bayer, Roche, Taiho.

L Moreira: No conflicts of interest.

F Mornex: Honoraria: Merck Serono, Lilly, Roche.

K Oberg: No conflicts of interest.

HG Palmer: No conflicts of interest.

H Prenen: No conflicts of interest.

J Raimbourg: Advisory boards, Speaker bureaux: Boehringer-Ingelheim, Roche, Novartis.

M Reig: Advisory boards, conferences, travel grants: Bayer.

S Roselló: No conflicts of interest.

T Seufferlein: Lectures fees, advisory boards, symposia presentations: Amgen, Celgene, Merck Serono, Roche, Bayer, Pfizer, Lilly.

J Tabernero: Consultancy or Advisory roles: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Imclone, Lilly, MSD, Merck Serono, Millennium, Novartis, Roche, Sanofi, Symphogen, Taiho.

N Tarazona: No conflicts of interest.

C Verslype: No conflicts of interest.

« Previous Page

Last update: 07 July 2016